Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Anixa Biosciences, Inc.

Anixa Biosciences is a biotechnology company focused on the treatment and prevention of cancer.

Anixa Biosciences

Anixa Biosciences (NASDAQ:ANIX) is a clinical stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company’s vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer--specifically triple negative breast cancer (TNBC), the most lethal form of the disease--as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization.

Anixa featured in POPSUGAR Health -What to Know About the Breast Cancer Vaccine | POPSUGAR Health                              

https://lnkd.in/e5hDfddR

#breastcancer #cancerresearch

Anixa announces #FDAapproval of individual patient IND for its #ovariancancer CAR-T therapy. Read press release here to learn more: https://bit.ly/3LCz3Qb

#CancerResearch #Immunotherapy

Anixa initiates $5 million stock repurchase program

"This share repurchase program reflects our confidence in the future outlook of our business, the soundness of our balance sheet, the strength of our clinical development pipeline and Anixa's long-term value," stated Dr. Amit Kumar, Chairman and CEO of Anixa. 

Read more here- https://bit.ly/3S9rzId

Anixa Announces Presentation on its #OvarianCancer CAR-T #ClinicalTrial at the International Gynecologic Cancer Society 2024 Annual Meeting being held on October 16-18, 2024

Read more here: https://bit.ly/3WhWW4k

#CancerResearch #Immunotherapy

$ANIX CEO Dr. Amit Kumar discusses immunotherapy and the Company's #breastcancer vaccine program with ROBERT “SULLY” SULLIVAN on BigBizShow. Watch interview here: http://bit.ly/4ek30la

#cancerresearch #oncology #Biotechnology

Anixa announces Japanese patent on #BreastCancer vaccine technology 

Read more here: https://bit.ly/465NfKZ

#patents  #cancerresearch #oncology #clinicalresearch #biotech

NASDAQ:ANIX

Anixa Biosciences

Last Close

3.38

25/09 14:28

Market Cap

75.22M

Beta: 0.95

Volume Today

2.79K

Avg: 87.17K

PE Ratio

−15.23

PFCF: −23.49

People Not Available